• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用利尿剂促使恶性腹水排出取决于腹水的特性。

Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics.

作者信息

Pockros P J, Esrason K T, Nguyen C, Duque J, Woods S

机构信息

Department of Medicine, Scripps Clinic and Research Foundation, La Jolla, California.

出版信息

Gastroenterology. 1992 Oct;103(4):1302-6. doi: 10.1016/0016-5085(92)91520-e.

DOI:10.1016/0016-5085(92)91520-e
PMID:1397889
Abstract

Serial ascites and plasma volumes were measured during diuresis in nine patients with ascites caused by peritoneal carcinomatosis, four patients with chylous malignant ascites, and three patients with portal hypertension-related ascites caused by massive hepatic metastases. Oral diuretics were given to achieve an adequate natriuresis on a sodium-restricted diet. During the study period (7.8 +/- 3.2 days), patients with peritoneal carcinomatosis and chylous ascites lost 0.49 +/- 0.31 and 0.51 +/- 0.42 kg/day in weight, respectively, with negligible change in ascites volumes (-0.03 +/- 0.11 and 0.02 +/- 0.09 L/day). Patients with ascites caused by massive hepatic metastasis lost 1.06 +/- 0.15 kg/day in weight (P = 0.01 for massive hepatic metastasis vs. peritoneal carcinomatosis) and 0.23 +/- 0.13 L/day of ascites (P less than 0.05 vs. other groups). Plasma volume changes were not significantly different among the three groups. Patients with edema (9/16) had a greater natriuresis and daily weight loss. Three patients with peritoneal carcinomatosis and one with chylous ascites developed renal dysfunction or symptomatic hypotension. No patient with massive hepatic metastasis developed these complications. In patients with ascites caused by peritoneal carcinomatosis or chylous malignant ascites there is no mobilization of ascites, whereas in patients with massive hepatic metastasis, ascites may be mobilized with diuretics.

摘要

在利尿过程中,对9例腹膜癌所致腹水患者、4例乳糜性恶性腹水患者和3例由大量肝转移引起的门静脉高压相关腹水患者进行了连续腹水和血浆容量测量。给予口服利尿剂以在限钠饮食基础上实现充分的钠利尿。在研究期间(7.8±3.2天),腹膜癌和乳糜性腹水患者体重分别以0.49±0.31和0.51±0.42kg/天的速度下降,腹水容量变化可忽略不计(-0.03±0.11和0.02±0.09L/天)。由大量肝转移引起腹水的患者体重以1.06±0.15kg/天的速度下降(大量肝转移组与腹膜癌组相比,P=0.01),腹水以0.23±0.13L/天的速度减少(与其他组相比,P<0.05)。三组间血浆容量变化无显著差异。有水肿的患者(9/16)钠利尿和每日体重下降更多。3例腹膜癌患者和1例乳糜性腹水患者出现肾功能不全或症状性低血压。大量肝转移患者未出现这些并发症。在腹膜癌或乳糜性恶性腹水引起腹水的患者中,腹水未被动员,而在大量肝转移患者中,利尿剂可能促使腹水排出。

相似文献

1
Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics.使用利尿剂促使恶性腹水排出取决于腹水的特性。
Gastroenterology. 1992 Oct;103(4):1302-6. doi: 10.1016/0016-5085(92)91520-e.
2
Ascitic fluid analysis in malignancy-related ascites.恶性肿瘤相关性腹水的腹水分析
Hepatology. 1988 Sep-Oct;8(5):1104-9. doi: 10.1002/hep.1840080521.
3
Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema.慢性肝病腹水患者的快速利尿:外周水肿的重要性。
Gastroenterology. 1986 Jun;90(6):1827-33. doi: 10.1016/0016-5085(86)90249-0.
4
Ascitic fluid analysis in hepatocellular carcinoma.肝细胞癌的腹水分析
Cancer. 1993 Aug 1;72(3):677-82. doi: 10.1002/1097-0142(19930801)72:3<677::aid-cncr2820720309>3.0.co;2-c.
5
A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.非氮质血症肝硬化患者腹水利尿治疗阶梯式护理方法中对螺内酯无反应的病理生理学解释。
Hepatology. 1991 Aug;14(2):231-6.
6
Malignant ascites: sonographic signs of peritoneal carcinomatosis.恶性腹水:腹膜癌转移的超声征象
Eur J Cancer. 1991;27(6):720-3. doi: 10.1016/0277-5379(91)90173-b.
7
Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.托伐普坦14天给药治疗肝性水肿腹水患者的疗效与安全性。
J Int Med Res. 2013 Jun;41(3):835-47. doi: 10.1177/0300060513480089. Epub 2013 May 17.
8
[Genesis of fibronectin in ascites--detection of cellular and plasma fibronectin in portal and malignant ascites].[腹水纤连蛋白的起源——门静脉性和恶性腹水中细胞性和血浆纤连蛋白的检测]
Z Gastroenterol. 1991 Jan;29(1):16-21.
9
Chemotherapy treatment of chyloperitoneum and peritoneal carcinomatosis due to cervical cancer--review of literature.宫颈癌所致乳糜性腹水和腹膜癌的化疗治疗——文献综述
Gynecol Oncol. 1996 Jun;61(3):448-50. doi: 10.1006/gyno.1996.0173.
10
Laminin concentration in ascites of patients with hepatic cirrhosis and peritoneal carcinomatosis.肝硬化和腹膜癌患者腹水中层粘连蛋白的浓度。
Braz J Med Biol Res. 2005 Feb;38(2):271-6. doi: 10.1590/s0100-879x2005000200016. Epub 2005 Feb 15.

引用本文的文献

1
Contemporary Management of Malignant Ascites.恶性腹水的当代管理
J Surg Res. 2025 Mar;307:157-175. doi: 10.1016/j.jss.2025.01.025. Epub 2025 Mar 3.
2
Advances in the treatment of malignant ascites in China.中国恶性腹水治疗的进展。
Support Care Cancer. 2024 Jan 11;32(2):97. doi: 10.1007/s00520-023-08299-w.
3
Is Low Volume Drainage of Ascites Associated With Improved Survival in Digestive System Cancer Patients With Malignant Ascites?-A Retrospective Cohort Study.低容量腹水引流是否与消化系统癌症合并恶性腹水患者的生存改善相关?一项回顾性队列研究。
J Palliat Care. 2023 Oct;38(4):473-480. doi: 10.1177/08258597231170049. Epub 2023 Apr 24.
4
Clinical risk factors for ascites in metastatic pancreatic cancer.转移性胰腺癌腹水的临床危险因素。
ESMO Open. 2023 Apr;8(2):101200. doi: 10.1016/j.esmoop.2023.101200. Epub 2023 Mar 28.
5
Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites.原发性肝外恶性肿瘤合并恶性腹水患者的临床特征和转归。
BMC Gastroenterol. 2022 Sep 5;22(1):410. doi: 10.1186/s12876-022-02487-4.
6
Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies.急诊科的胰胆恶性肿瘤:急性并发症和肿瘤急症的处理。
J Gastrointest Cancer. 2022 Dec;53(4):1050-1065. doi: 10.1007/s12029-021-00718-7. Epub 2021 Oct 14.
7
Symptom Management in Pancreatic Cancer.胰腺癌的症状管理。
Curr Treat Options Oncol. 2021 Jan 2;22(1):8. doi: 10.1007/s11864-020-00801-4.
8
Incidence of Hyponatremia in Patients With Indwelling Peritoneal Catheters for Drainage of Malignant Ascites.留置腹腔导管引流恶性腹水患者低钠血症的发生率。
JAMA Netw Open. 2020 Oct 1;3(10):e2017859. doi: 10.1001/jamanetworkopen.2020.17859.
9
Management of drainage for malignant ascites in gynaecological cancer.妇科癌症恶性腹水的引流管理
Cochrane Database Syst Rev. 2019 Dec 11;12(12):CD007794. doi: 10.1002/14651858.CD007794.pub3.
10
A survey of practice in management of malignancy-related ascites in Japan.日本恶性肿瘤相关性腹水管理实践调查。
PLoS One. 2019 Aug 9;14(8):e0220869. doi: 10.1371/journal.pone.0220869. eCollection 2019.